Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

aletz Feb. 3 at 10:24 AM

$MLTX I just would like to warn folks not to be disappointed if the SP doesn't move much despite the conference. Conferences have very little impact on the stock price unless a completely new positive data is presented. Only pennystocks and shitpharmcos spike from a conference. Just sit back and relax and keep loading for the long term.

1 · Reply

perplex Feb. 3 at 8:46 AM

$MLTX A few earnings today and tomorrow of interest.

0 · Reply

perplex Feb. 3 at 8:40 AM

$MLTX Do we get a little surge in price today or tomorrow before conference? I expect by tomorrow EOD.

0 · Reply

cranberry1 Feb. 3 at 5:40 AM

$MLTX when they are done loading and close out the short, that's when they'll let it run.

1 · Reply

AXMO Feb. 3 at 5:21 AM

$MLTX

0 · Reply

cranberry1 Feb. 3 at 5:20 AM

$MLTX

0 · Reply

Mr_GA Feb. 3 at 5:12 AM

$MLTX Back and forth, back and forth. Come on MoonLake, I just pulled the $17 out of storage this morning, now I need to pull the $16 back out. Make up your mind please!

0 · Reply

Bigbadjohn89 Feb. 3 at 3:36 AM

$MLTX $69

1 · Reply

MarkGoldw Feb. 3 at 2:46 AM

$MLTX Cantor mentions MoonLake Immunotherapeutics (NASDAQ:MLTX) reached a market cap of $2.X billion-$2.5 billion after Phase 2 data, that also when there was skepticism regarding the size of the Hidradenitis Suppurativa market.

0 · Reply

Bigpapa46 Feb. 3 at 2:39 AM

$MLTX People on this board has already made points about this today but Insider Monkey had MLTX on a “biotech stocks under $20 to buy” list just a few days ago, talking about hedge fund ownership and Phase 3 progress "1-31-2026". In fact it was #3 of 20. Then this morning, right after the FDA Fast Track news, they drop a headline recycling an old Goldman Sachs sell note like it’s new information "1hr and 36 minutes later". Same stock, same facts, totally different tone depending on timing. Just a reminder they are a paid service so focus on the actual science and FDA progress, not the garbage

3 · Reply

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Jan 27, 2026, 7:30 AM EST - 6 days ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 23, 2026, 7:30 AM EST - 10 days ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Jan 9, 2026, 8:15 AM EST - 24 days ago

MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

Jan 8, 2026, 2:06 PM EST - 25 days ago

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

Dec 15, 2025, 10:46 AM EST - 7 weeks ago

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

Dec 11, 2025, 10:08 AM EST - 7 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 11, 2025, 8:54 AM EST - 7 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 8, 2025, 1:23 PM EST - 2 months ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 8, 2025, 9:00 AM EST - 2 months ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

Dec 5, 2025, 8:18 AM EST - 2 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 5, 2025, 8:06 AM EST - 2 months ago

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

Dec 4, 2025, 3:01 PM EST - 2 months ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 4, 2025, 9:00 AM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

Dec 3, 2025, 7:46 AM EST - 2 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 2, 2025, 5:29 PM EST - 2 months ago

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

CPTN

Dec 1, 2025, 5:52 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 1, 2025, 3:18 PM EST - 2 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 12:26 PM EST - 2 months ago

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

APP FIX KTOS TW VRSK

Nov 30, 2025, 7:45 AM EST - 2 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 28, 2025, 5:50 PM EST - 2 months ago

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Nov 27, 2025, 2:15 PM EST - 2 months ago

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

Nov 24, 2025, 6:08 AM EST - 2 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 18, 2025, 12:33 AM EST - 2 months ago

MoonLake: Ignore The Panic, Catch The Upside

Nov 14, 2025, 6:08 AM EST - 2 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 10, 2025, 8:15 AM EST - 3 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 6:06 AM EST - 3 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 5, 2025, 7:11 AM EST - 3 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:00 AM EST - 3 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 1, 2025, 7:08 AM EDT - 3 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Oct 28, 2025, 9:51 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

aletz Feb. 3 at 10:24 AM

1 · Reply

perplex Feb. 3 at 8:46 AM

$MLTX A few earnings today and tomorrow of interest.

0 · Reply

perplex Feb. 3 at 8:40 AM

$MLTX Do we get a little surge in price today or tomorrow before conference? I expect by tomorrow EOD.

0 · Reply

cranberry1 Feb. 3 at 5:40 AM

$MLTX when they are done loading and close out the short, that's when they'll let it run.

1 · Reply

AXMO Feb. 3 at 5:21 AM

$MLTX

0 · Reply

cranberry1 Feb. 3 at 5:20 AM

$MLTX

0 · Reply

Mr_GA Feb. 3 at 5:12 AM

$MLTX Back and forth, back and forth. Come on MoonLake, I just pulled the $17 out of storage this morning, now I need to pull the $16 back out. Make up your mind please!

0 · Reply

Bigbadjohn89 Feb. 3 at 3:36 AM

$MLTX $69

1 · Reply

MarkGoldw Feb. 3 at 2:46 AM

0 · Reply

Bigpapa46 Feb. 3 at 2:39 AM

3 · Reply

RunnerUp1 Feb. 3 at 2:28 AM

$MLTX let’s not shoot the messenger. The fact that there was ONE rushed out/sent out immediately after the good news to control the price means either the shorts are fearful or someone is not finish accumulating. That someone was desperate and had to pull up/recycle an old silly downgrade to cap the price. Funny game they play…. Let’s see how long they can hold the MC at $1.1B. What’s the TAM for SLK again?

2 · Reply

cranberry1 Feb. 3 at 1:55 AM

$MLTX 70% give or take held by institutions and insiders, my bet is that number will climb back up to 90% before any big move. Currently 21 million for the people....and mm to f*ck with. Buy and hold

0 · Reply

cranberry1 Feb. 3 at 1:46 AM

$MLTX what a lively board. At this point in the game a 1.1billion mc is a joke. Where it should be now 3billion minimum. Where it will be bought out at anyone's guess. Very safe buy at these levels. Buy and hold

0 · Reply

Bigpapa46 Feb. 3 at 1:16 AM

$MLTX Just two more days until the conference begins a moment where the waiting gives way to clarity. Looking forward to whatever data emerges and how it may shape the path ahead.

0 · Reply

goon9074 Feb. 3 at 1:01 AM

$MLTX A PR to bury anyone short tomorrow morning would be awesome! Like they refused a 7.1bb offer. I mean that's exactly what happened when they refused merck's offer last year. By June 3rd there were 3 or 4 different articles written

1 · Reply

fresh2021 Feb. 3 at 12:32 AM

$MLTX Goldman Sachs thought MLTX “high‑risk” after the VELA‑2 miss — that trial materially raised approvability uncertainty for HS — but FDA signals (Type B feedback and Fast Track for PPP) materially reduce some regulatory risk and add upside optionality. Don't let them get your shares.

1 · Reply

goon9074 Feb. 3 at 12:27 AM

$MLTX Remember guys, i went dark last week cause i was really involved in the negotiations, stocktwits knows this, cause I'm special. Anyway, a premium of 550% was turned down even though it's more than what we wanted a few short months ago. It's a dogfight my minions. Keep lapping up the nonsense i feed you, down ever stop. I'm going to keep buying, even though if i was so wealthy and had all this information months ago, I could have bought all the shares i wanted at $6. Anyway, keep the faith. See you next week. Buyout soon, very soon, believe me.

1 · Reply

maildriver Feb. 3 at 12:00 AM

$MLTX I was able to scrounge enough together to buy another 500 shares at 15.79 today but my question is I thought buyout offers have to be disclosed to shareholders if they are material enough to greatly affect the stock price.

1 · Reply

Arxidia Feb. 2 at 11:45 PM

$MLTX ditto 👇🏼

0 · Reply

septrading Feb. 2 at 11:35 PM

$MLTX if there is a leak mentioning any price this week, my bet is on someone like Centerview Partners. Anything bearish will be GS or Merck originated.

2 · Reply

cranberry1 Feb. 2 at 11:28 PM

$MLTX kind of crazy they kept it flat with that news. Long term buy and hold

2 · Reply

Bigpapa46 Feb. 2 at 11:22 PM

$MLTX well at least the sentiment turned bullish

0 · Reply

Market Cap	1.01B
Revenue (ttm)	0.00
Net Income (ttm)	-118.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.25

Volume	1,570,900
Avg Vol	2,456,272
Day's Range	N/A - N/A
Shares Out	64.23M
Stochastic %K	36%
Beta	1.21
Analysts	Sell
Price Target	$20.28